Wednesday, August 10, 2022
No menu items!
HomeHealth ScienceExome sequencing permits detection of related pharmacogenetic variants in epileptic sufferers

Exome sequencing permits detection of related pharmacogenetic variants in epileptic sufferers

[ad_1]

  • Hesselink D. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Therapeutics. 2003;74:245–54.

    CAS 
    Article 

    Google Scholar
     

  • Relling MV, Evans WE. Pharmacogenomics within the clinic. Nature 2015;526:343–50.

    CAS 
    Article 

    Google Scholar
     

  • Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a current replace on medical implications and endogenous results. Pharmacogenomics J. 2013;13:1–11.

    CAS 
    Article 

    Google Scholar
     

  • Relling MV, Klein TE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Caudle KE. The medical pharmacogenetics implementation consortium: 10 years later. Clin Pharmacol Ther. 2020;107:171–5.

    Article 

    Google Scholar
     

  • Financial institution PCD, Caudle KE, Swen JJ, Gammal RS, Whirl‐Carrillo M, Klein TE, et al. Comparability of the rules of the medical pharmacogenetics implementation Consortium and the Dutch pharmacogenetics Working group. Clin Pharm Ther. 2018;103:599–618.

    CAS 
    Article 

    Google Scholar
     

  • Visscher H, Ross CJD, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, et al. Canadian Pharmacogenomics Community for Drug Security Consortium Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in youngsters. J Clin Oncol. 2012;30:1422–8.

    Article 

    Google Scholar
     

  • Picard N, Boyer JC, Etienne‐Grimaldi MC, Barin‐Le GC, Thomas F, Loriot MA. Pharmacogenetics‐based mostly customized remedy: ranges of proof and proposals from the French Community of Pharmacogenetics (RNPGx). Therapie. 2017;72:185–92.

    Article 

    Google Scholar
     

  • Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl Ok, Thorn CF, et al. Pharmacogenomics Data for Personalised Drugs. Clin Pharm Ther. 2012;92:414–7.

    CAS 
    Article 

    Google Scholar
     

  • Thijs RD, Surges R, O’Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393:689–701.

    Article 

    Google Scholar
     

  • Orsini A, Zara F, Striano P. Current advances in epilepsy genetics. Neurosci Lett. 2018;667:4–9.

    CAS 
    Article 

    Google Scholar
     

  • Symonds JD, Zuberi SM, Johnson MR. Advances in epilepsy gene discovery and implications for epilepsy prognosis and therapy. Curr Opin Neurol. 2017;30:193–9.

    Article 

    Google Scholar
     

  • Bruel A-L, Levy J, Elenga N, Defo A, Favre A, Lucron H, et al. INTU -related oral-facial-digital syndrome kind VI: A confirmatory report. Clin Genet. 2018;93:1205–9.

    CAS 
    Article 

    Google Scholar
     

  • Thevenon J, Duffourd Y, Masurel-Paulet A, Lefebvre M, Feillet F, El Chehadeh-Djebbar S, et al. Diagnostic odyssey in extreme neurodevelopmental problems: towards medical whole-exome sequencing as a first-line diagnostic check. Clin Genet. 2016;89:700–7.

    CAS 
    Article 

    Google Scholar
     

  • Bruel A-L, Nambot S, Quéré V, Vitobello A, Thevenon J, et al. Elevated diagnostic and new genes identification consequence utilizing analysis reanalysis of singleton exome sequencing. Eur J Hum Genet. 2019;27:1519–31.

    CAS 
    Article 

    Google Scholar
     

  • Cousin MA, Matey ET, Blackburn PR, Boczek NJ, McAllister TM, Kruisselbrink TM, et al. Pharmacogenomic findings from medical complete exome sequencing of diagnostic odyssey sufferers. Mol Genet Genom Med. 2017;5:269–79.

    Article 

    Google Scholar
     

  • Blom S. trigeminal neuralgia: its therapy with a brand new anticonvulsant drug (G-32883). Lancet. 1962;279:839–40.

    Article 

    Google Scholar
     

  • Arif H, Buchsbaum R, Weintraub D, Koyfman S, Salas-Humara C, Bazil CW, et al. Comparability and predictors of rash related to 15 antiepileptic medication. Neurology. 2007;68:1701–9.

    CAS 
    Article 

    Google Scholar
     

  • Karnes JH, Rettie AE, Somogyi AA, Huddart R, Fohner AE, Formea CM, et al. Medical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 Replace. Clin. Pharmacol. Ther. 2020;96:542–8.


    Google Scholar
     

  • Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is related to HLA-B*1502 allele in Thai inhabitants. Epilepsia. 2008;49:2087–91.

    Article 

    Google Scholar
     

  • Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. A marker for Stevens–Johnson syndrome. Nature. 2004;428:486.

    CAS 
    Article 

    Google Scholar
     

  • Anzenbacher P, Anzenbacherová E. Cytochromes P450 and metabolism of xenobiotics: CMLS. Cell Mol Life Sci. 2001;58:737–47.

    CAS 
    Article 

    Google Scholar
     

  • Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African–American exhibiting toxicity to phenytoin. Pharmacogenetics Genomics. 2001;11:803–8.

    CAS 
    Article 

    Google Scholar
     

  • Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): medical penalties, evolutionary points and purposeful variety. Pharmacogenomics J. 2005;5:6–13.

    CAS 
    Article 

    Google Scholar
     

  • Karnes JH, Rettie AE, Somogyi AA, Huddart R, Fohner AE, Formea CM, et al. Medical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Replace. Clin Pharmacol Therap. 2020;109:302–9.

    Article 

    Google Scholar
     

  • Thauvin-Robinet C, Thevenon J, Nambot S, Delanne J, Kuentz P, Bruel AL, et al. Secondary actionable findings recognized by exome sequencing: anticipated impression on the organisation of care from the examine of 700 consecutive exams. Eur J Hum Genet. 2019;27:1197–214.

    Article 

    Google Scholar
     

  • Ruden DM, Cingolani P, Patel VM, Coon M, Nguyen T, Land SJ, et al. Utilizing Drosophila melanogaster as a Mannequin for Genotoxic Chemical Mutational Research with a New Program, SnpSift. Entrance Gene. 2012;3:35.


    Google Scholar
     

  • Ka S, Lee S, Hong J, Cho Y, Sung J, Kim HN, et al. HLAscan: genotyping of the HLA area utilizing next-generation sequencing knowledge. BMC Bioinforma. 2017;18:1–11.

    Article 

    Google Scholar
     

  • Giancarlo GM, Venkatakrishnan Ok, Granda BW, von Moltke LL, Greenblatt DJ. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur J Clin Pharm. 2001;57:31–36.

    CAS 
    Article 

    Google Scholar
     

  • Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 within the stereoselective metabolism of phenytoin to its main metabolite. Drug Metab Dispos. 1996;24:1401–3.

    CAS 
    PubMed 

    Google Scholar
     

  • van der Weide J, Steijns LS, van Weelden MJ, de Haan Ok. The impact of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics. 2001;11:87–91.


    Google Scholar
     

  • Kudo T, Endo Y, Taguchi R, Yatsu M, Ito Ok. Metronidazole reduces the expression of cytochrome P450 enzymes in HepaRG cells and cryopreserved human hepatocytes. Xenobiotica. 2015;45:413–9.

    CAS 
    Article 

    Google Scholar
     

  • Fohner AE, Ranatunga DK, Thai KK, Lawson BL, Rischx N, Oni-Orisan A, et al. Assessing the medical impression of CYP2C9 pharmacogenetic variation on phenytoin prescribing follow and affected person response in an built-in well being system. Pharmacogenet Genomics. 2019;29:192–9.

    CAS 
    Article 

    Google Scholar
     

  • Dorado P, López-Torres E, Peñas-Lledó EM, Martínez-Antón J, Llerena A. Neurological toxicity after phenytoin infusion in a pediatric affected person with epilepsy: affect of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. Pharmacogenomics J. 2013;13:359–61.

    CAS 
    Article 

    Google Scholar
     

  • Cresteil T, Beaune P, Kremers P, Celier C, Guengerich FP, Leroux J-P. Immunoquantification of epoxide hydrolase and cytochrome P-450 isozymes in fetal and grownup human liver microsomes. Eur J Biochem. 1985;151:345–50.

    CAS 
    Article 

    Google Scholar
     

  • Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG. et al. Developmental Expression of Human Hepatic CYP2C9 and CYP2C19. J Pharm Exp Ther. 2004;308:965–74.

    CAS 
    Article 

    Google Scholar
     

  • McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl J Med. 2011;364:1134–43.

    CAS 
    Article 

    Google Scholar
     

  • Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA genotype and carbamazepine-induced cutaneous antagonistic drug reactions: a scientific evaluate. Clin Pharm Ther. 2012;92:757–65.

    CAS 
    Article 

    Google Scholar
     

  • Zhou Y, Krebs Ok, Milani L, Lauschke VM. World Frequencies of Clinically Essential HLA Alleles and Their Implications For the Value‐Effectiveness of Preemptive Pharmacogenetic Testing. Clin Pharmacol Ther. 2021;109:160–74.

    Article 

    Google Scholar
     

  • Xue Y, Ankala A, Wilcox WR, Hegde MR. Fixing the molecular diagnostic testing conundrum for Mendelian problems within the period of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing. Genet Med. 2015;17:444–51.

    CAS 
    Article 

    Google Scholar
     

  • [ad_2]

    RELATED ARTICLES

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    Most Popular

    Recent Comments